News

Study data suggested that up to 80% of patients with Parkinson disease may have ophthalmologic symptoms, suggesting that wider use of early identification tools may improve timely treatment.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.

Statistically significant associations between stress-related disorders were identified in those with Alzheimer disease, but not with Parkinson disease or amyotrophic lateral sclerosis.

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.

Telemedicine has potential to play a key role in diagnosis and testing during the outbreak of COVID-19

Patients opted for nontriptan acute medications such as opioids and nonsteroidal anti-inflammatory drugs instead of staying on triptans at 12- and 24-month follow-ups.

As neurologists and other specialists may increasingly be called upon to serve as general hospitalists in the wake of the COVID-19 pandemic, keeping health care workers healthy becomes paramount.

The Tuberous Sclerosis Alliance (TS Alliance) have prepared an FAQ to address concerns from the tuberous sclerosis complex (TSC) community regarding the COVID-19 outbreak.

The oral calcitonin gene-related peptide receptor antagonist was approved in late February and comes in 8-tablet packs for treatment of 8 migraine attacks with a single, 75-mg dose.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 13, 2020.

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine discussed the daily challenges patients with narcolepsy face.

Our patients have a huge need for access to specialists, yet unfortunately, there is a huge shortage of headache specialists.

A proof‐of‐concept assessment showed that women with chronic migraine and insomnia can be reasonably treated with digital cognitive behavioral therapy for insomnia, with data suggesting it may improve both conditions.

The Engage Therapeutics product met its primary end point in the StATES study, with an onset of action for ceasing seizure activity of approximately 30 seconds, on average.

The director of the Sleep Clinic at Boston Children’s Hospital discussed the lack of clinical research for pediatric sleep disorders and what the current landscape looks like.

Study results suggest that the plasma P-tau181 biomarker may be an effective noninvasive biomarker for Alzheimer disease, with prognostic and diagnostic value for use in both clinical practice and clinical trials.

Data suggests that access to endovascular thrombectomy centers within 15 minutes is limited to less than one-fifth of the population, pointing to a need for improved access and bypass methodologies.